Zolinza is indicated for treatment of cutaneous manifestations in patients with Cutaneous T- Cell Lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

INN:

Subtype:

Lymphoma, T-Cell, Cutaneous (CTCL)

License:

FDA

Class:

Histone deacetylase inhibitor

R/R

PIhttps://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf 

1. Approved Labelling 

Zolinza is indicated for treatment of cutaneous manifestations in patients with Cutaneous T- Cell Lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.

2. Treatment Regimen

The recommended dose is 400 mg orally once daily with food.

If patient is intolerant to therapy, the dose may be reduced to 300 mg orally once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.

3. AE/Warnings

Please see section 5 of the PI

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.